Last edition
News about "CDMO"
Morepen Laboratories Completes First Phase of API and CDMO Capacity Expansion Ahead of Schedule
Morepen Laboratories has increased its installed reactor capacity from 535 KL to 614 KL, strengthening manufacturing readiness for commercial CDMO scale-up and supporting its API business and future customer programs.<br />
CDMO | 07/09/2026 | By News Bureau | 559
Akums Drugs and Pharmaceuticals Reports 35.4 Percent EBITDA Growth in Q1 FY27
Akums Drugs and Pharmaceuticals starts FY27 on a strong note, reporting robust revenue, EBITDA and PAT growth as its CDMO business continues to drive performance.
CDMO | 11/08/2026 | By News Bureau
Gland Pharma and Neuland Partner for Sterile API Manufacturing
Gland Pharma and Neuland Laboratories have partnered to expand sterile Active Pharmaceutical Ingredient (API) manufacturing through a new state-of-the-art current Good Manufacturing Practice (GMP) sterile manufacturing suite.
CDMO | 06/08/2026 | By News Bureau
Piramal Pharma Reports Q1 FY27 Results
Piramal Pharma has reported its standalone and consolidated Q1 FY27 financial results, highlighting its performance for the quarter ended June 30, 2026.
CDMO | 30/07/2026 | By News Bureau | 117
Shilpa Biologicals has launched PartnerPower, a proprietary platform offering real-time visibility into process development and Good Manufacturing Practice (GMP) manufacturing, setting a new benchmark for transparency in CDMO operations.
CDMO | 24/06/2026 | By News Bureau | 141
Made Scientific and Pluristyx Partner to Advance iPSC Cell Therapies
Made Scientific and Pluristyx have launched a strategic partnership to streamline iPSC-derived cell therapy development and manufacturing. By integrating Pluristyx’s clinical-grade iPSC platform with Made Scientific’s CDMO services, the collaboration provides developers with a single-source pathway from cell line development to commercial supply.
CDMO | 08/06/2026 | By News Bureau | 170
OrganaBio Acquires Excellos Assets to Establish Bicoastal Cell Therapy Manufacturing Platform
The acquisition expands cGMP manufacturing, PBMC isolation and cryopreservation capabilities across the US to support cell therapy developers from preclinical to commercial stages.
CDMO | 16/05/2026 | By News Bureau | 135
OneSource and Orbicular Receive US FDA Tentative Approval for Generic Semaglutide
OneSource and Orbicular secure US FDA tentative approval for generic semaglutide injection, advancing ANDA filing for Ozempic with manufacturing support from OneSource.
CDMO | 22/04/2026 | By News Bureau | 289
Morepen Laboratories Bags Zero-Observation USFDA Inspection for Fourth Time
Morepen Laboratories clears its fourth consecutive USFDA inspection at the Masulkhana facility with zero observations (NIL 483), reinforcing its CDMO strength following a INR 825 crore global manufacturing mandate.
CDMO | 21/04/2026 | By News Bureau | 378
Piramal Pharma Solutions Expands ADC Capabilities with Ajinomoto Bio-Pharma Services Pact
Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to accelerate ADC development and manufacturing, enabling access to AJICAP technology.
CDMO | 20/04/2026 | By News Bureau | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy